Issue 3/2023
Including PIH articles on Progress in pathophysiology and treatment of thrombocytopenia
Content (21 Articles)
Detection of Candida albicans in the peripheral blood smear of a diffuse large B cell lymphoma patient
Shoya Arai, Takeshi Osawa, Takuji Matsuo, Kimiko Nogi, Haruko Tashiro
Inclusion of thymic Langerhans cell histiocytosis in the “5 Ts” of the differential diagnosis of anterior mediastinal mass
Kenichi Sakamoto, Kentaro Fujimori, Osamu Miyazaki, Takako Yoshioka, Akihiro Yoneda, Kimikazu Matsumoto, Yoko Shioda
Progress in pathophysiological understanding and treatment of thrombocytopenia
Hirokazu Kashiwagi
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura
Masayuki Kubo, Masanori Matsumoto
Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
Laura M. Venier, Bianca Clerici, Anna-Lise Bissola, Dimpy Modi, Stefan D. Jevtic, Michael Radford, Syed Mahamad, Ishac Nazy, Donald M. Arnold
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
Si Jing Chen, Naoshi Sugimoto, Koji Eto
Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia
Yukinori Nakamura, Takehiko Mori, Shinichi Kako, Hirohito Yamazaki, Yoshinobu Kanda, Naoyuki Uchida, Masatsugu Tanaka, Yuichiro Nawa, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Yasushi Onishi
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
Yoshitaka Miyakawa, Kazunori Imada, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Akihito Yonezawa, Shigeki Fujitani, Yoshiyuki Ogawa, Tadashi Matsushita, Hidesaku Asakura, Kenji Nishio, Kodai Suzuki, Yasuhiro Hashimoto, Hidenori Murakami, Sayaka Tahara, Tomoyuki Tanaka, Masanori Matsumoto
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy
Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Yen-Lin Liu, Jia-Ruey Tsai, Chen-Hua Tsai, Chao-Neng Cheng, Yeu-Chin Chen
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies
Ana C. Oliveira, Josep Maria Roncero, Christelle Ferrá, Janilson Do Nascimento, Marta Rodriguez-Luaces, Maite Encuentra, Eva Domingo-Domenech, Patricia López, David Gallardo, Josep Maria Ribera, Josep Sarrá, Anna Sureda, Eva González-Barca
Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia
Masamitsu Yanada, Satoshi Yamasaki, Takaaki Konuma, Shohei Mizuno, Naoyuki Uchida, Daishi Onai, Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Tetsuya Eto, Kazuhiro Ikegame, Masashi Sawa, Yuta Katayama, Toshiro Kawakita, Makoto Onizuka, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Shingo Yano
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
Koji Kato, Nobuharu Fujii, Shinichi Makita, Hideki Goto, Junya Kanda, Kazuyuki Shimada, Koichi Akashi, Koji Izutsu, Takanori Teshima, Natsuko Fukuda, Tokuhito Sumitani, Shota Nakamura, Hiroyuki Sumi, Shinji Shimizu, Yasuyuki Kakurai, Kenji Yoshikawa, Kensei Tobinai, Noriko Usui, Kiyohiko Hatake
Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors
Ryu Yanagisawa, Tsuneaki Hirakawa, Noriko Doki, Kazuhiro Ikegame, Ken-ichi Matsuoka, Takahiro Fukuda, Hirohisa Nakamae, Shuichi Ota, Nobuhiro Hiramoto, Jun Ishikawa, Takahide Ara, Masatsugu Tanaka, Yuhki Koga, Toshiro Kawakita, Yumiko Maruyama, Yoshinobu Kanda, Masayuki Hino, Yoshiko Atsuta, Hiromasa Yabe, Nobuhiro Tsukada
Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience
Mengni Guo, Jieying Liu, Pamela Clark, Sarfraz Ahmad, Rushang Patel, Juan Carlos Varela, Shahram Mori
Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation
Shojiro Haji, Motoaki Shiratsuchi, Akiko Takamatsu, Mariko Tsuda, Hiroki Muta, Toru Masuda, Yasuhiro Nakashima, Yoshihiro Ogawa
Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment
Nihal Karadaş, Şerife Şebnem Önen Göktepe, İlke Baş, Dilek Ece, Hamiyet Hekimci Özdemir, Can Balkan, Kaan Kavaklı, Yeşim Aydinok, Deniz Yilmaz Karapinar
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Michael J. Hochman, B. Douglas Smith, Theodoros Karantanos, Evan M. Braunstein, Ivana Gojo, Tania Jain, Michael B. Streiff, Alison R. Moliterno, Amy E. DeZern
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion
Takashi Oyama, Kazuki Taoka, Akira Chiba, Yosuke Masamoto, Masako Ikemura, Akira Honda, Hiroaki Maki, Mineo Kurokawa
Correction to: Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation
Mutsumi Nishida, Junichi Sugita, Shuichiro Takahashi, Takahito Iwai, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Tatsunori Horie, Ryosuke Sakano, Hitoshi Shibuya, Isao Yokota, Akihiro Iguchi, Takanori Teshima
Correction: Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series
Yoshinobu Kanda, Takehiko Mori, Atsushi Narita, Kevin D. Wolter, Hiroki Yoshimatsu, Kazuma Nishimura